
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is positioned for attractive fundamental growth because its core businesses are shifting toward higher-margin, differentiated products in dry eye, premium IOLs, and premium daily contact lenses, while the company’s broad portfolio of over 100 eye-care products supports share gains across end markets. MIEBO is a key driver, with durable prescription momentum and modeled revenue of $395MM in 2026 and $786MM in 2029, while XIIDRA’s gross-to-net improvement helps offset formulary pressure and sustain the pharma franchise. The surgical and contact lens businesses add further upside, as enVista Envy has resumed rapid growth after its recall, premium daily SiHy grew 23% y/y in 1Q'26 and 16% y/y in 2Q'26, and projected EBITDA of $1.2Bn reflects operating leverage and margin expansion potential.
Bears say
Bausch & Lomb is facing a negative setup because several core growth drivers appear vulnerable, including MIEBO missing its FY2026 guide, weaker-than-expected contact lens demand, and softer consumer sentiment that could pressure its OTC business. Its Surgical segment also looks exposed if premium IOL adoption slows, since that would weaken the product mix and compress margins, while the company’s broader eye-care portfolio still depends on legacy dry-eye treatments like RESTASIS that have slow onset and tolerability issues. In addition, the bioactive contact lens pipeline and next-generation innovation carry execution risk, and with contact lens wearers already showing a ~20-25% first-year discontinuation rate, the stock’s growth and margin expansion case looks fragile.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares